Q1 2025 ALK-Abello A/S Earnings Call Transcript
Key Points
- Revenue grew by 12% to DKK1.5 billion, with all sales regions experiencing double-digit growth.
- Global tablet sales increased by 22%, driven by higher volumes and shipments, particularly to Japan.
- Earnings improved by 50% in local currencies to DKK469 million, yielding an EBIT margin of 31%.
- The pediatric indication for the house dust mite tablet, ACARIZAX, contributed to growth with encouraging initial market response.
- Free cash flow almost tripled to DKK330 million, indicating strong financial health and operational efficiency.
- Sales of SCIT products decreased slightly in Europe, partly due to fewer-than-expected new patients.
- No SCIT product shipments to China in Q1, leading to an 85% decrease in SCIT revenue in international markets.
- Jext sales in Europe were temporarily affected by lower replacement rates for adrenaline pens in the U.K. and other markets.
- The EBIT margin is expected to decrease from Q1 levels as Q1 is historically the most profitable quarter.
- Potential macroeconomic uncertainties from trade and tariff wars could impact future performance, although currently deemed manageable.
/-- -
Hello, everyone, and welcome to this presentation of ALK's Q1 results and full year outlook for 2025. Thank you all for joining us, and let's turn to slide number 2 with an introduction to speakers. My name is Per Plotnikof. I'm Head of Investor Relations. And with me today are CEO, Peter Halling; and CFO, Claus Steensen Solje.
We'll first be sharing a few highlights from the quarter, followed by a closer look at the markets, product trends and financials. And we will then provide an update on recent progresses on our pediatric agenda and on the neffy partnership before we move to the full year outlook. As usual, we will end the presentation with a Q&A session. And to get started, I'll hand over to Peter on slide number 3 for the highlights. Please go ahead, Peter.
/- -
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
